Parathyroid hormone and phosphorus overload in uremia: Impact on cardiovascular system

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1437-1445

  Custódio, Melani R ^a   Koike, Marcia K ^a   Neves, Katia R ^a   Dos Reis, Luciene M ^a   Graciolli, Fabiana G ^a   Neves, Carolina L ^a   Batista, Daniella G ^a   Magalhães, Andrea O ^a   Hawlitschek, Philippe ^a   Oliveira, Ivone B ^a   Dominguez, Wagner V ^a   Moysés, Rosa M A ^a   Jorgetti, Vanda ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

FGF 23; hyperphosphatemia; left ventricular hypertrophy; parathyroid hormone; vascular calcification

Indexed keywords

3 NITROTYROSINE; ALPHA ACTIN; ANGIOTENSIN II; CREATININE; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PARATHYROID HORMONE; PHOSPHORUS; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEMATOCRIT; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS; UREMIA; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FIBROSIS; IMMUNOENZYME TECHNIQUES; MALE; NEPHRECTOMY; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHORUS, DIETARY; RATS; RATS, WISTAR; UREMIA;

EID: 84859305054     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr447     Document Type: Article

References (34)

1. TonelliM,WiebeN,CulletonBet al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047 (Pubitemid 44036188)
2. US Renal Data System. USRDS 2006 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2006 3.
3. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008; 21: 300-307
4. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16: 85-94 (Pubitemid 37356820)
5. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569-582 (Pubitemid 30167013)
6. Yao Q, Pecoits-Filho R, Lindholm B et al. Traditional and nontraditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004; 38: 405-416 (Pubitemid 39551351)
7. Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000; 101: 1002-1006 (Pubitemid 30131702)
8. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538 (Pubitemid 35286260)
9. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 836-843
10. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-592
11. Neves KR, Graciolli FG, dos Reis LM et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270 (Pubitemid 46884255)
12. Saleh FN, Schirmer H, Sundsfjord J et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24: 2054-2060 (Pubitemid 37420453)
13. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J AmSoc Nephrol 2003; 14(9 Suppl 4):S300-S304 (Pubitemid 37052394)
14. Neves KR, Graciolli FG, dos Reis LM et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004; 66: 2237-2244 (Pubitemid 41115286)
15. Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial 2008; 21: 308-318
16. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009; 75: 800-808
17. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998; 37: 34-41 (Pubitemid 28122613)
18. Hagstrom E, Hellman P, Larsson TE et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009; 119: 2765-2771
19. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218 (Pubitemid 39031360)
20. Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981; 67: 1215-1227 (Pubitemid 11090564)
21. Amann K, Törnig J, Kugel B et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: 1296-1301 (Pubitemid 36349995)
22. Beck GR Jr., Moran E, Knecht N. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2. Exp Cell Res 2003; 288: 288-300 (Pubitemid 36966077)
23. Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol 2006; 17(Suppl 3): S255-S261 24. (Pubitemid 44865258)
24. Yuen D, Pierratos A, Richardson RM et al. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant 2006; 21: 1407-1412
25. Amann K Törnig J Flechtenmacher C et al. Blood-pressureindependent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant 1995; 10: 2043-2048
26. Schluter KD, Piper HM. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 1992; 263: H1739-H1746 (Pubitemid 23030726)
27. Uzawa T, Hori M, Ejiri S et al. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) on rat bone. Bone 1995; 16: 477-484
28. Wang N, Yang J, Yu X et al. Radial artery calcification in end-stage renal disease patients is associated with deposition of osteopontin and diminished expression of alpha-smooth muscle actin. Nephrology (Carlton) 2008; 13: 367-375
29. Inaba M, Okuno S, Imanishi Y et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17: 1506-1513 (Pubitemid 44387485)
30. Graciolli FG, Neves KR, dos Reis LM et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant 2009; 24: 1416-1421
31. Detillieux KA, Sheikh F, Kardami E et al. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003; 57: 8-19 (Pubitemid 36009431)
32. Liu L, Pasumarthi KB, Padua RR et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. Am J Physiol 1995;268: H1927-H1938
33. Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010; 25: 1376-1381
34. Canziani ME, Tomiyama C, Higa A et al. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011; 31:26-32